Fish oil supplements

JAMA

Volumn 312, Issue 8, 2014, Pages 839-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID ETHYL ESTER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PLACEBO; TRIACYLGLYCEROL;

ADVERSE OUTCOME; BLEEDING TIME; CARDIOVASCULAR DISEASE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPEPSIA; ERUCTATION; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; HYPERTRIGLYCERIDEMIA; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SUPPLEMENTATION; THROMBOCYTE AGGREGATION;

CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; FISH OILS; HUMANS;

EID: 84907303501     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.9758     Document Type: Letter

References (4)

1. Fish oil supplements. Med Lett Drugs Ther. 2012;54(1401):83-84.
2. Roncaglioni MC, Tombesi M, Avanzini F, et al; Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl JMed. 2013;368(19):1800-1808.
3. Kwak SM, Myung SK, Lee YJ, Seo HG; Korean Meta-analysis Study Group. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: ameta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172(9):686-694.
4. Isosapent ethyl (Vascepa) for severe hypertriglyceridemia. Med Lett Drugs Ther. 2013;55 (1415):33-34.